|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03759 PHARMARON
Nominal 
12.260 -0.500 (-3.918%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 12,275,775 | 6.394% | 11,537,996 | 10,266,288 | 7,443,770 | 5,133,597 |
| Cost of Sales | (8,126,520) | 9.181% | (7,443,176) | (6,517,012) | (4,771,726) | (3,217,484) |
| Gross Profit | 4,149,255 | 1.329% | 4,094,820 | 3,749,276 | 2,672,044 | 1,916,113 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (116,486) | 225.153% | (35,825) | (21,157) | (10,269) | (14,823) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (123,256) | 5814.395% | (2,084) | (33,851) | 71,845 | (24,565) | |
| Profit / (Loss) before Taxation | 2,091,263 | 13.786% | 1,837,887 | 1,666,391 | 1,910,996 | 1,319,370 | |
| Taxation | (377,104) | 47.245% | (256,106) | (314,254) | (290,919) | (172,378) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 79,192 | 310.003% | 19,315 | 22,467 | 40,952 | 25,391 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 1,793,351 | 12.008% | 1,601,096 | 1,374,604 | 1,661,029 | 1,172,383 | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 170,087 | 14.422% | 148,649 | 132,099 | 18,666 | (50,210) |
| Depreciation & Amortisation | 1,145,412 | 13.566% | 1,008,588 | 766,063 | 577,673 | 438,016 |
| Directors' Emoluments | -- | -- | 6,916 | 6,955 | 21,653 | 13,637 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 101.330 | 12.178% | 90.330 | 77.500 | 93.253 | 65.889 |
| DPS (cts) | 20.000 | -- | 20.000 | 20.000 | 20.000 | 13.333 |
| Dividend Payout Ratio (%) | 19.737% | -- | 22.141% | 25.806% | 21.447% | 20.236% |
| Cash flow per share ($) | -- | -- | 1.554 | 1.209 | 1.156 | 1.390 |
| NBV per share ($) | 7.690 | -- | 6.917 | 5.793 | 5.558 | 4.962777 |
| Remarks: | Real time quote last updated: 16/04/2025 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,793,351 |
| %Change | 12.008% |
| EPS / (LPS) | RMB 1.013 |
| NBV Per Share (¥) | RMB 7.690 |